Healio Minute Podcast, DME/Retina Edition: Top Headlines - Week of July 8, 2024
Click Here to Manage Email Alerts
In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more.
Read the full coverage here:
FDA approves Vabysmo prefilled syringe for retinal diseases
VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates
FDA approves Eylea biosimilar FYB203/Ahzantive
VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study
ANI Pharmaceuticals to acquire Alimera Sciences
References:
Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Healio Interviews
Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.
Collapse
Read more about
Click Here to Manage Email Alerts
